Table of Content

1 INTRODUCTION 16
1.1 OBJECTIVES OF THE STUDY 16
1.2 MARKET DEFINITION 16
1.3 MARKET SCOPE 16
1.3.1 MARKETS COVERED 17
1.3.2 YEARS CONSIDERED FOR THE STUDY 17
1.4 CURRENCY 18
1.5 STAKEHOLDERS 18
1.6 LIMITATIONS 18

2 RESEARCH METHODOLOGY 19
2.1 RESEARCH APPROACH 19
2.1.1 SECONDARY RESEARCH 20
2.1.1.1 Key data from secondary sources 20
2.1.2 PRIMARY RESEARCH 21
2.1.2.1 Key data from primary sources 21
2.1.2.2 Breakdown of primaries 22
2.1.2.3 Key industry insights 22
2.2 MARKET SIZE ESTIMATION 23
2.3 DATA TRIANGULATION APPROACH 24
2.4 MARKET SHARE ESTIMATION 25
2.5 ASSUMPTIONS FOR THE STUDY 25

3 EXECUTIVE SUMMARY 26

4 PREMIUM INSIGHTS 29
4.1 CLINICAL RISK GROUPING SOLUTIONS: MARKET OVERVIEW 29
4.2 CLINICAL RISK GROUPING SOLUTIONS MARKET: GEOGRAPHIC
GROWTH OPPORTUNITIES 30
4.3 REGIONAL MIX: CLINICAL RISK GROUPING SOLUTIONS MARKET (2019–2024) 30
4.4 CLINICAL RISK GROUPING SOLUTIONS MARKET: DEVELOPED VS. DEVELOPING MARKETS 31

5 MARKET OVERVIEW 32
5.1 INTRODUCTION 32
5.2 MARKET DYNAMICS 32
5.2.1 MARKET DRIVERS 33
5.2.1.1 Increasing focus on risk management 33
5.2.1.2 Rising usage of big data solutions 33
5.2.2 RESTRAINTS 34
5.2.2.1 Lack of infrastructure 34
5.2.3 OPPORTUNITIES 34
5.2.3.1 Increasing physician burnout due to documentation needs 34
5.2.3.2 Increasing focus on AI and machine learning 35
5.2.4 CHALLENGES 35
5.2.4.1 Scarcity of skilled healthcare IT professionals 35
5.2.4.2 Patient data privacy concerns 35
5.2.5 BURNING ISSUE 36
5.2.5.1 Implementation of solutions reduces administrative expenses but increases the burden on patients 36

6 CLINICAL RISK GROUPING SOLUTIONS MARKET, BY PRODUCT 37
6.1 INTRODUCTION 38
6.2 SCORECARDS & VISUALIZATION TOOLS 39
6.2.1 NEED TO INCREASE PATIENT ACCURACY AND FORECAST RISKS ARE DRIVING DEMAND FOR SCORECARDS & VISUALIZATION TOOLS 39
6.3 DASHBOARD ANALYTICS SOLUTIONS 40
6.3.1 DASHBOARD ANALYTICS SEGMENT TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 40
6.4 RISK REPORTING SOLUTIONS 42
6.4.1 INCREASING ADOPTION OF RISK MANAGEMENT SOLUTIONS BY HEALTHCARE PROVIDERS TO FUEL MARKET GROWTH 42

7 CLINICAL RISK GROUPING SOLUTIONS MARKET, BY DEPLOYMENT MODEL 44
7.1 INTRODUCTION 45
7.2 PRIVATE CLOUD 46
7.2.1 HIGH DATA SECURITY OF PRIVATE CLOUD MODELS IS DRIVING
MARKET GROWTH 46
7.3 PUBLIC CLOUD 47
7.3.1 PRICE-EFFECTIVENESS OF PUBLIC OVER PRIVATE CLOUDS HAS
DRIVEN END-USER PREFERENCE 47
7.4 HYBRID CLOUD 48
7.4.1 HYBRID CLOUD ARCHITECTURE PROVIDE FLEXIBILITY AND THE ABILITY
TO AVOID VENDOR LOCK-IN 48

8 CLINICAL RISK GROUPING SOLUTIONS MARKET, BY END USER 49
8.1 INTRODUCTION 50
8.2 HOSPITALS 51
8.2.1 HOSPITALS ARE THE LARGEST END USERS OF THE CLINICAL RISK GROUPING SOLUTIONS MARKET 51
8.3 PAYERS 52
8.3.1 PAYERS USE CLINICAL RISK GROUPING SOLUTIONS FOR RISK MANAGEMENT, IDENTIFYING CLAIMS TRENDS, AND MAXIMIZING PAYMENT ACCURACY 52
8.4 AMBULATORY CARE CENTERS 54
8.4.1 IMPLEMENTATION OF MANDATES TO COMPLY WITH QUALITY MEASURES TO SUPPORT THE ADOPTION OF CLINICAL RISK GROUPING SOLUTIONS IN AMBULATORY CARE CENTERS 54
8.5 LONG-TERM CARE CENTERS 55
8.5.1 GROWING NUMBER OF LONG-TERM CARE CENTERS TO DRIVE
MARKET GROWTH 55
8.6 OTHER END USERS 57

9 CLINICAL RISK GROUPING SOLUTIONS MARKET, BY REGION 59
9.1 INTRODUCTION 60
9.2 NORTH AMERICA 61
9.2.1 US 64
9.2.1.1 US dominates the North American clinical risk grouping
solutions market 64
9.2.2 CANADA 66
9.2.2.1 Growing need for cost containment in healthcare will propel market growth 66
9.3 EUROPE 68
9.3.1 GERMANY 71
9.3.1.1 Infrastructural development and focus on risk management have driven market growth in Germany 71
9.3.2 UK 73
9.3.2.1 Favorable regulatory outlook has pushed the adoption of HCIT solutions in the UK 73
9.3.3 FRANCE 75
9.3.3.1 Initiatives taken by the French government to promote the use of healthcare IT solutions will drive market growth 75
9.3.4 REST OF EUROPE (ROE) 76
9.4 ASIA PACIFIC 78
9.4.1 ASIA IS EXPECTED TO WITNESS HIGH GROWTH IN POPULATION AND DEMAND FOR HEALTHCARE SERVICES 78
9.5 LATIN AMERICA 80
9.5.1 COUNTRIES SUCH AS BRAZIL AND MEXICO ARE EXPLORING NEW METHODS TO MANAGE CLINICAL INFORMATION 80
9.6 MIDDLE EAST AND AFRICA 82
9.6.1 MIDDLE EASTERN COUNTRIES ARE INVESTING SIGNIFICANTLY IN HCIT INFRASTRUCTURAL DEVELOPMENT 82
?

10 COMPETITIVE LANDSCAPE 84
10.1 INTRODUCTION 84
10.2 COMPETITIVE LEADERSHIP MAPPING 85
10.2.1 VISIONARY LEADERS 85
10.2.2 INNOVATORS 85
10.2.3 DYNAMIC DIFFERENTIATORS 85
10.2.4 EMERGING COMPANIES 86
10.3 COMPANY ANALYSIS, BY PRODUCT AND END USER 87
10.4 COMPETITIVE SITUATIONS AND TRENDS 87

11 COMPANY PROFILE 90
(Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View)*
11.1 3M COMPANY 90
11.2 OPTUM INC. (SUBSIDIARY OF UNITEDHEALTH GROUP INC.) 93
11.3 NUANCE COMMUNICATIONS 97
11.4 CONDUENT INCORPORATED 100
11.5 CERNER CORPORATION 103
11.6 HBI SOLUTIONS, INC. 106
11.7 4S INFORMATION SYSTEMS LTD. 108
11.8 JOHNS HOPKINS UNIVERSITY 109
11.9 LIGHTBEAM HEALTH SOLUTIONS, LLC 110
11.10 DYNAMIC HEALTHCARE SYSTEMS, INC. 113
11.11 PERAHEALTH, INC. 114
11.12 HEALTH CATALYST INC. 116
11.13 EVOLENT HEALTH 118
*Business Overview, Products Offered, Recent Developments, SWOT Analysis, MnM View might not be captured in case of unlisted companies.

12 APPENDIX 121
12.1 MARKET SIZING & VALIDATION APPROACH 121
12.2 DISCUSSION GUIDE 123
12.3 KNOWLEDGE STORE: MARKETSANDMARKETS’ SUBSCRIPTION PORTAL 126
12.4 AVAILABLE CUSTOMIZATIONS 128
12.5 RELATED REPORTS 128
12.6 AUTHOR DETAILS 129



List of Figures



FIGURE 1 CLINICAL RISK GROUPING SOLUTIONS MARKET SEGMENTATION 17
FIGURE 2 RESEARCH DESIGN 19
FIGURE 3 BREAKDOWN OF PRIMARY INTERVIEWS: BY COMPANY TYPE DESIGNATIONS, AND REGION 22
FIGURE 4 BOTTOM-UP APPROACH 23
FIGURE 5 TOP-DOWN APPROACH 23
FIGURE 6 DATA TRIANGULATION METHODOLOGY 24
FIGURE 7 CLINICAL RISK GROUPING SOLUTIONS MARKET, BY PRODUCT 2019 VS. 2024 (USD MILLION) 26
FIGURE 8 CLINICAL RISK GROUPING SOLUTIONS MARKET, BY DEPLOYMENT MODEL 2019 VS. 2024 (USD MILLION) 27
FIGURE 9 CLINICAL RISK GROUPING SOLUTIONS MARKET, BY END USER 2019 VS. 2024 (USD MILLION) 27
FIGURE 10 GEOGRAPHICAL SNAPSHOT OF THE CLINICAL RISK GROUPING
SOLUTIONS MARKET 28
FIGURE 11 INCREASING FOCUS ON RISK MANAGEMENT IS THE MAJOR FACTOR DRIVING THE ADOPTION OF CLINICAL RISK GROUPING SOLUTIONS 29
FIGURE 12 ASIA PACIFIC MARKET TO REGISTER THE HIGHEST GROWTH DURING THE FORECAST PERIOD 30
FIGURE 13 NORTH AMERICA WILL CONTINUE TO DOMINATE THE CLINICAL RISK GROUPING SOLUTIONS MARKET IN 2024 30
FIGURE 14 ASIA PACIFIC MARKET TO REGISTER HIGHER GROWTH RATES DURING THE FORECAST PERIOD 31
FIGURE 15 CLINICAL RISK GROUPING SOLUTIONS MARKET: DRIVERS, RESTRAINTS, OPPORTUNITIES & CHALLENGES 32
FIGURE 16 HEALTHCARE DATA BREACHES IN THE US (2016-2019) 34
FIGURE 17 SCORECARD AND VISUALIZATION TOOLS SEGMENT TO DOMINATE THE CLINICAL RISK GROUPING SOLUTIONS MARKET IN 2019 38
FIGURE 18 PRIVATE CLOUD TO HOLD THE LARGEST SHARE OF THE CLINICAL RISK GROUPING SOLUTIONS MARKET DURING THE FORECAST PERIOD 45
FIGURE 19 CLINICAL RISK GROUPING SOLUTIONS MARKET, BY END USER, 2019 VS. 2024 50
FIGURE 20 CLINICAL RISK GROUPING SOLUTIONS MARKET: GEOGRAPHIC SNAPSHOT 60
FIGURE 21 NORTH AMERICA: CLINICAL RISK GROUPING SOLUTIONS MARKET SNAPSHOT 62
FIGURE 22 EUROPE: CLINICAL RISK GROUPING SOLUTIONS MARKET SNAPSHOT 69
FIGURE 23 KEY DEVELOPMENTS IN THE CLINICAL RISK GROUPING SOLUTIONS MARKET BETWEEN 2016 AND 2019 84
FIGURE 24 CLINICAL RISK GROUPING SOLUTIONS MARKET: COMPETITIVE
LEADERSHIP MAPPING (2018) 86
FIGURE 25 3M AND OPTUM ARE THE LEADING PLAYERS IN THE CLINICAL RISK
GROUPING SOLUTIONS MARKET 87
FIGURE 26 3M COMPANY: COMPANY SNAPSHOT 90
FIGURE 27 OPTUM INC.: COMPANY SNAPSHOT 93
FIGURE 28 NUANCE COMMUNICATIONS: COMPANY SNAPSHOT 97
?
FIGURE 29 CONDUENT INCORPORATED: COMPANY SNAPSHOT 100
FIGURE 30 CERNER: COMPANY SNAPSHOT 103
FIGURE 31 EVOLENT HEALTH: COMPANY SNAPSHOT 118

 

List of Tables



TABLE 1 EXCHANGE RATES UTILIZED FOR CONVERSION TO USD 18
TABLE 2 CLINICAL RISK GROUPING SOLUTIONS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 38
TABLE 3 SCORECARDS AND VISUALIZATION TOOLS: KEY BRANDS 39
TABLE 4 SCORECARDS & VISUALIZATION TOOLS MARKET, BY REGION 2017–2024 (USD MILLION) 40
TABLE 5 DASHBOARD ANALYTICS: KEY BRANDS 41
TABLE 6 DASHBOARD ANALYTICS SOLUTIONS MARKET, BY REGION 2017–2024 (USD MILLION) 41
TABLE 7 RISK REPORTING: KEY BRANDS 42
TABLE 8 RISK REPORTING SOLUTIONS MARKET, BY REGION, 2017–2024 (USD MILLION) 43
TABLE 9 CLINICAL RISK GROUPING SOLUTIONS MARKET, BY DEPLOYMENT MODEL 2017–2024 (USD MILLION) 45
TABLE 10 PRIVATE CLOUD-DEPLOYED CLINICAL RISK GROUPING SOLUTIONS MARKET BY COUNTRY/REGION, 2017–2024 (USD MILLION) 46
TABLE 11 PUBLIC CLOUD-DEPLOYED CLINICAL RISK GROUPING SOLUTIONS MARKET BY COUNTRY/REGION, 2017–2024 (USD MILLION) 47
TABLE 12 HYBRID CLOUD-DEPLOYED CLINICAL RISK GROUPING SOLUTIONS MARKET BY COUNTRY/REGION, 2017–2024 (USD MILLION) 48
TABLE 13 CLINICAL RISK GROUPING SOLUTIONS MARKET, BY END USER 2017–2024 (USD MILLION) 50
TABLE 14 CLINICAL RISK GROUPING SOLUTIONS FOR HOSPITALS 51
TABLE 15 CLINICAL RISK GROUPING SOLUTIONS MARKET FOR HOSPITALS BY COUNTRY/REGION, 2017–2024 (USD MILLION) 52
TABLE 16 CLINICAL RISK GROUPING SOLUTIONS FOR PAYERS 53
TABLE 17 CLINICAL RISK GROUPING SOLUTIONS MARKET FOR PAYERS BY COUNTRY/REGION, 2017–2024 (USD MILLION) 54
TABLE 18 CLINICAL RISK GROUPING SOLUTIONS FOR AMBULATORY CARE CENTERS 55
TABLE 19 CLINICAL RISK GROUPING SOLUTIONS MARKET FOR AMBULATORY CARE CENTERS, BY COUNTRY/REGION, 2017–2024 (USD MILLION) 55
TABLE 20 CLINICAL RISK GROUPING SOLUTIONS FOR LONG-TERM CARE CENTERS 56
TABLE 21 CLINICAL RISK GROUPING SOLUTIONS MARKET FOR LONG-TERM CARE CENTERS, BY COUNTRY/REGION, 2017–2024 (USD MILLION) 57
TABLE 22 CLINICAL RISK GROUPING SOLUTIONS MARKET FOR OTHER END USERS BY COUNTRY/REGION, 2017–2024 (USD MILLION) 58
TABLE 23 CLINICAL RISK GROUPING SOLUTIONS MARKET, BY REGION, 2017–2024 (USD MILLION) 61
TABLE 24 NORTH AMERICA: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY COUNTRY, 2017–2024 (USD MILLION) 63
TABLE 25 NORTH AMERICA: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 63
TABLE 26 NORTH AMERICA: CLINICAL RISK GROUPING SOLUTIONS MARKET BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 63
TABLE 27 NORTH AMERICA: CLINICAL RISK GROUPING SOLUTIONS MARKET BY END USER, 2017–2024 (USD MILLION) 64
TABLE 28 US: KEY MACROINDICATORS 65
TABLE 29 US: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 65
TABLE 30 US: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 65
TABLE 31 US: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY END USER 2017–2024 (USD MILLION) 66
TABLE 32 CANADA: KEY MACROINDICATORS 67
TABLE 33 CANADA: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 67
TABLE 34 CANADA: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 67
TABLE 35 CANADA: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY END USER 2017–2024 (USD MILLION) 68
TABLE 36 EUROPE: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY COUNTRY 2017–2024 (USD MILLION) 70
TABLE 37 EUROPE: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 70
TABLE 38 EUROPE: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 70
TABLE 39 EUROPE: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY END USER 2017–2024 (USD MILLION) 71
TABLE 40 GERMANY: KEY MACROINDICATORS 71
TABLE 41 GERMANY: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 72
TABLE 42 GERMANY: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 72
TABLE 43 GERMANY: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY END USER 2017–2024 (USD MILLION) 72
TABLE 44 UK: KEY MACROINDICATORS 73
TABLE 45 UK: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 73
TABLE 46 UK: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 74
TABLE 47 UK: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY END USER 2017–2024 (USD MILLION) 74
TABLE 48 FRANCE: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 75
TABLE 49 FRANCE: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 75
TABLE 50 FRANCE: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY END USER 2017–2024 (USD MILLION) 76
TABLE 51 ROE: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY PRODUCT 2017–2024 (USD MILLION) 76
TABLE 52 ROE: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 77
TABLE 53 ROE: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY END USER 2017–2024 (USD MILLION) 77
TABLE 54 ASIA PACIFIC: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 78
TABLE 55 ASIA PACIFIC: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 79
TABLE 56 ASIA PACIFIC: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY END USER, 2017–2024 (USD MILLION) 79
TABLE 57 LATIN AMERICA: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY PRODUCT, 2017–2024 (USD MILLION) 80
TABLE 58 LATIN AMERICA: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 81
TABLE 59 LATIN AMERICA: CLINICAL RISK GROUPING SOLUTIONS MARKET, BY END USER, 2017–2024 (USD MILLION) 81
TABLE 60 MIDDLE EAST AND AFRICA: CLINICAL RISK GROUPING SOLUTIONS MARKET BY PRODUCT, 2017–2024 (USD MILLION) 82
TABLE 61 MIDDLE EAST AND AFRICA: CLINICAL RISK GROUPING SOLUTIONS MARKET BY DEPLOYMENT MODEL, 2017–2024 (USD MILLION) 83
TABLE 62 MIDDLE EAST AND AFRICA: CLINICAL RISK GROUPING SOLUTIONS MARKET BY END USER, 2017–2024 (USD MILLION) 83
TABLE 63 PRODUCT LAUNCHES AND ENHANCEMENTS (2017–2019) 87
TABLE 64 ACQUISITIONS, JOINT VENTURES, AND MERGERS (2018–2019) 88
TABLE 65 COLLABORATIONS, AGREEMENTS, AND PARTNERSHIPS (2018–2019) 89
TABLE 66 EXPANSIONS (2017) 89